Federico Damilano
Pfizer (United States)(US)Torino e-district(IT)University of Turin(IT)
Publications by Year
Research Areas
Cardiac Fibrosis and Remodeling, Cardiomyopathy and Myosin Studies, Cardiac electrophysiology and arrhythmias, Cardiovascular Function and Risk Factors, MicroRNA in disease regulation
Most-Cited Works
- → miR-222 Is Necessary for Exercise-Induced Cardiac Growth and Protects against Pathological Cardiac Remodeling(2015)388 cited
- → Integrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110γ(2011)192 cited
- → Adipose tissue mitochondrial dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatosteatosis, and cardiovascular complications(2014)174 cited
- → PI3K-C2γ is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling(2015)174 cited
- → Activin type II receptor signaling in cardiac aging and heart failure(2019)142 cited
- → PI3K inhibition in inflammation: Toward tailored therapies for specific diseases(2010)123 cited